CAMBRIDGE, Mass., Nov. 13, 2018 (GLOBE NEWSWIRE) — LogicBio Therapeutics, Inc. (NASDAQ:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in patients with significant unmet medical need, today announced that Fred Chereau, President and Chief Executive Officer of LogicBio, will present a corporate overview at the Jefferies 2018 London Conference on Thursday, November 15, 2018 at 5:20 p.m. GMT in London.
A live audio webcast of the presentation will be available on the Investors section of LogicBio’s website at https://investor.logicbio.com, where it will be archived for approximately 30 days.
About LogicBio Therapeutics
LogicBio Therapeutics is a genome editing company focused on developing medicines to durably treat rare diseases in patients with significant unmet medical needs using, GeneRide™, its proprietary technology platform. GeneRide™ enables the site-specific integration of a therapeutic transgene in a nuclease-free and promotorless approach by relying on the native process of homologous recombination to drive lifelong expression. Headquartered in Cambridge, Massachusetts, LogicBio is committed to developing medicines that will transform the lives of pediatric patients and their families.
Contacts:
Michael Schaffzin
Stern Investor Relations
michael@sternir.com
212-362-1200
Stephanie Simon
Ten Bridge Communications
stephanie@tenbridgecommunications.com
617-581-9333